Transforming cancer care at all stages of the disease
AJ Patel
7-year stage IV lung cancer survivor

Transforming cancer care at all stages of the disease

We are dedicated to helping patients at all stages of cancer live longer and healthier, through the power of blood tests and the data they unlock. Today our FDA-approved test helps inform treatment decisions for patients with advanced cancer. Our tests also detect residual and recurrent disease for patients with early-stage cancer, and will soon screen to find cancer at its earliest and most treatable.

Learn more
February 2, 2023

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guard...

A strategic collaboration on the development, regulatory approval and commercialization of the Guardant360® CDx and Guardant360Tis...
READ MORE
February 1, 2023

Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on...

Guardant Health will report financial results for the fourth quarter and full year 2022 after market close on Thursday, February 2...
READ MORE
January 31, 2023

Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to e...

Guardant GalaxyTM, a suite of advanced analytical technologies developed internally and through outside partnerships to enhance th...
READ MORE
January 30, 2023

Guardant Health receives FDA approval for Guardant360® CDx as companion diagnost...

The U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic to iden...
READ MORE
January 19, 2023

Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly ant...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, is partnering with The Royal Marsden NHS Foundation Trus...
READ MORE
January 17, 2023

Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of it...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of bloo...
READ MORE
See all press releases
Precision oncology

Delivering on the promise for patients

Precision oncology is redefining cancer care by driving a more personalized and data-driven approach that improves on traditional standards of care. From using biomarkers to inform treatment in advanced cancer, to using circulating tumor DNA to not only assess response to treatment, but detect signs of remaining cancer and even identify the earliest signs of cancer, precision oncology is helping patients across all stages of the disease.

Learn more
Products

Blood tests are at the core of our mission

Blood is at the center of transforming cancer care by holding insights that can improve clinical outcomes. Over 300,000 of our blood tests have been performed by 12,000 doctors to date. Our commercially available tests help inform treatment decisions for patients with advanced cancer, monitor treatment response, detect residual and recurrent disease in patients with early-stage cancer, and soon may help screen for cancer before symptoms appear. Our products also help pharmaceutical companies develop the next generation of cancer therapies.

    • “Our focus is always on what will have the greatest impact on patients.”
    Helmy Eltoukhy, co-CEO
    Careers

    Together we can help conquer cancer

    When you join our team, you become part of a mission that impacts so many personally: conquering cancer with data. We are passionate about serving patients and their families through the power of blood and the life-changing information it holds. Guardant Health is hiring bright minds in diverse fields to solve some of the most profound challenges in human health today.

    Learn more